Clinical Significance of Extended-spectrum β-lactamaseproducing Bacteria in First Pediatric Febrile Urinary Tract Infections and Differences between Age Groups
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Extended-spectrum β-lactamase-producing bacteria-induced urinary tract infections are increasing and require more potent antibiotics such as carbapenems. We evaluated the clinical significance of extended-spectrum β-lactamase urinary tract infection in children younger than 5 years to select proper antibiotics and determine prognostic factors. Differences were compared between age groups. Methods: We retrospectively studied 288 patients with their first febrile urinary tract infection when they were younger than 5 years. Patients were divided into extended-spectrum β-lactamase-positive and extended-spectrum β-lactamasenegative urinary tract infection groups. Clinical characteristics and outcomes were compared between the groups; an infant group was separately analyzed (onset age younger than 3 months). Results: Extended-spectrum β-lactamase urinary tract infection occurred in 11 % patients who had more frequent previous hospitalization (P =0.02) and higher recurrence rate (P =0.045). During the antimicrobial susceptibility test, the extendedspectrum β-lactamase-positive urinary tract infection group showed resistance to third-generation cephalosporins; however, 98% patients responded clinically. In the infant group, extended-spectrum β-lactamase-positive urinary tract infection occurred in 13% patients and was associated with a longer pre-onset hospitalization history (P =0.002), higher C-reactive protein level (P =0.04), and higher recurrence rate (P =0.02) than that in the older group. Conclusion: Extended-spectrum β-lactamase urinary tract infection requires more attention because of its higher recurrence rate. The antimicrobial susceptibility test demonstrated resistance to third-generation cephalosporins, but they can be used as first-line empirical antibiotics because of their high clinical response rate. Aminoglycosides can be second-line antibiotics before starting carbapenems when third-generation cephalosporins do not show bactericidal effects for extended- spectrum β-lactamase urinary tract infection.
Abstract
Purpose: Extended-spectrum β-lactamase-producing bacteria-induced urinary tract infections are increasing and require more potent antibiotics such as carbapenems. We evaluated the clinical significance of extended-spectrum β-lactamase urinary tract infection in children younger than 5 years to select proper antibiotics and determine prognostic factors. Differences were compared between age groups. Methods: We retrospectively studied 288 patients with their first febrile urinary tract infection when they were younger than 5 years. Patients were divided into extended-spectrum β-lactamase-positive and extended-spectrum β-lactamasenegative urinary tract infection groups. Clinical characteristics and outcomes were compared between the groups; an infant group was separately analyzed (onset age younger than 3 months). Results: Extended-spectrum β-lactamase urinary tract infection occurred in 11 % patients who had more frequent previous hospitalization (P =0.02) and higher recurrence rate (P =0.045). During the antimicrobial susceptibility test, the extendedspectrum β-lactamase-positive urinary tract infection group showed resistance to third-generation cephalosporins; however, 98% patients responded clinically. In the infant group, extended-spectrum β-lactamase-positive urinary tract infection occurred in 13% patients and was associated with a longer pre-onset hospitalization history (P =0.002), higher C-reactive protein level (P =0.04), and higher recurrence rate (P =0.02) than that in the older group. Conclusion: Extended-spectrum β-lactamase urinary tract infection requires more attention because of its higher recurrence rate. The antimicrobial susceptibility test demonstrated resistance to third-generation cephalosporins, but they can be used as first-line empirical antibiotics because of their high clinical response rate. Aminoglycosides can be second-line antibiotics before starting carbapenems when third-generation cephalosporins do not show bactericidal effects for extended- spectrum β-lactamase urinary tract infection.
참고문헌 (25)
- Megged O, "Extended-spectrum beta-lactamase-producing bacteria causing community-acquired urinary tract infections in children", Pediatr Nephrol, 29, pp.1583~1587 (2014)
- Roberts KB, "A synopsis of the American Academy of Pediatrics'practice parameter on the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children", Pediatr Rev, 20, pp.344~347 (1999)
- Doganis D, "Does early treatment of urinary tract infection prevent renal damage?", Pediatrics, 120, pp.e922~e928 (2007)
- Peco-Antic A, "In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis", Srp Arh Celok Lek, 140, pp.321~325 (2012)
- -lactamase producing Escherichia coli: changing epidemiology and clinical impact, "Curr Opin Infect Dis", 2010, 320~326
- Lautenbach E, "Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae", Clin Infect Dis, 33, pp.1288~1294 (2001)
- Dayan N, "Urinary tract infections caused by community-acquired extended-spectrum beta-lactamase-producing and nonproducing bacteria: a comparative study", J Pediatr, 163, pp.1417~1421 (2013)
- Shaikh S, "Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment", Saudi J Biol Sci, 22, pp.90~101 (2015)
- Fan NC, "Rise of community-onset urinary tract infection caused by extendedspectrum beta-lactamase-producing Escherichia coli in children", J Microbiol Immunol Infect, 47, pp.399~405 (2014)
- Han SB, "Aminoglycoside therapy for childhood urinary tract infection due to extendedspectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae", BMC Infect Dis, 15, pp.414~ (2015)
- Cheng MF, "Urinary tract infection in infants caused by extended-spectrum beta-lactamase-producing Escherichia coli: comparison between urban and rural hospitals", Pediatr Nephrol, 31, pp.1305~1312 (2016)
- Dotis J, "Urinary tract infections caused by extended-spectrum betalactamaseproducing bacteria in children: a matched casecontrol study", Turk J Pediatr, 55, pp.571~574 (2013)
- Kizilca O, "Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children", Pediatr Int, 54, pp.858~862 (2012)
- Stein R, "Urinary tract infections in children: EAU", ESPU guidelines, 2015, pp.67, 546~558
- Rodriguez-Bano J, "Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients", J Clin Microbiol, 42, pp.1089~1094 (2004)
- Du B, "Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome", Intensive Care Med, 28, pp.1718~1723 (2002)
- Ramphal R, "Extended-spectrum beta-lactamases and clinical outcomes: current data", Clin Infect Dis, 42(Suppl 4), pp.S164~S172 (2006)
- Vinks AA, "Fundamentals of antimicrobial pharmacokinetics and pharmacodynamics", pp.137~146 (2014), Springer
- Gentry LO, "Cephalosporins in urinary tract infection", Drugs, 34(Suppl 2), pp.154~163 (1987)
- Pitout JD, "Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern", Lancet Infect Dis, 8, pp.159~166 (2008)
- Rupp ME, "Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment", Drugs, 63, pp.353~365 (2003)
- Rahal JJ, "Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella", Jama, 280, pp.1233~1237 (1998)
- Lee SO, "Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study", Antimicrob Agents Chemother, 48, pp.224~228 (2004)
- Lahlaoui H, "Epidemiology of Enterobacteriaceae producing CTX-M type extended spectrum beta-lactamase (ESBL)", Med Mal Infect, 44, pp.400~404 (2014)
- Wong-Beringer A, "Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime", Clin Infect Dis, 34, pp.135~146 (2002)